Balance Sheet Components (Tables)

3 Months Ended

Mar. 31, 2025

Inventory consists of the following (in thousands):


	March 31, 2025		December 31, 2024
Raw materials	$	3,026	$	3,030
Work in progress	15,817		16,089
Finished goods	3,575		3,284
Total inventory	$	22,418	$	22,403

Schedule of Finite Lived Intangible Assets

The components of the Company’s intangible assets were as follows (in thousands, except for weighted-average remaining amortization period):


	March 31, 2025
	Gross Carrying Value		Accumulated Amortization		Net Carrying Amount		Weighted-Average Remaining Amortization Period (Years)
Commercial milestones	$	59,000	$	(8,235)	$	50,765	12.3
Developed technology	226,620		(33,998)		192,622		10.4
Assembled workforce	970		(512)		458		1.4
Total intangible assets	$	286,590	$	(42,745)	$	243,845	10.8


	December 31, 2024
	Gross Carrying Value		Accumulated Amortization		Net Carrying Amount		Weighted-Average Remaining Amortization Period (Years)
Commercial milestones	$	59,000	$	(7,092)	$	51,908	12.6
Developed technology	226,620		(29,248)		197,372		10.7
Assembled workforce	970		(431)		539		1.7
Total intangible assets	$	286,590	$	(36,771)	$	249,819	11.1

Schedule of Estimated Future Amortization Expense Associated with Intangible Assets

The following table summarizes the estimated future amortization expense associated with the Company’s intangible assets as of March 31, 2025 (in thousands):


	Amount
2025 (remaining nine months)	17,924
2026	23,791
2027	23,575
2028	23,575
2029	23,575
Thereafter	131,405
	$	243,845

Schedule of Accrued Expenses

Accrued expenses consist of the following (in thousands):


	March 31, 2025		December 31, 2024
Accrued sales deductions	$	43,132	$	37,361
Accrued compensation and related benefits	16,599		32,248
Accrued professional service fees	13,969		12,545
Accrued contract manufacturing and non-clinical costs	8,304		7,555
Accrued royalties payable	10,088		9,361
Accrued clinical trials	9,843		7,148
Accrued interest	5,271		2,108
Accrued loss on firm purchase commitments	2,088		1,898
Operating lease liabilities, current	1,644		1,709
Accrued milestone payment	5,000		—
Total accrued expenses and other current liabilities	$	115,938	$	111,933

Schedule of Other Noncurrent Liabilities

Other liabilities consist of the following (in thousands):


	March 31, 2025		December 31, 2024
Noncurrent accrued sales deductions and other	$	9,952	$	—
Noncurrent accrued loss on firm purchase commitments	3,948		2,509
Total other liabilities	$	13,900	$	2,509